Research ExplorerPublicationsSPINK1 expression is tightly linked to 6q15- and 5q21-delete...

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence

Standard

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. / Grupp, Katharina; Diebel, Franz; Sirma, Hüseyin; Simon, Ronald; Breitmeyer, Karin; Steurer, Stefan; Hube-Magg, Claudia; Prien, Kristina; Pham, Taher; Weigand, Philipp; Michl, Uwe; Heinzer, Hans; Kluth, Martina; Minner, Sarah; Tsourlakis, Maria Christina; Izbicki, Jakob R; Sauter, Guido; Schlomm, Thorsten; Wilczak, Waldemar.

In: PROSTATE, Vol. 73, No. 15, 01.11.2013, p. 1690-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grupp, K, Diebel, F, Sirma, H, Simon, R, Breitmeyer, K, Steurer, S, Hube-Magg, C, Prien, K, Pham, T, Weigand, P, Michl, U, Heinzer, H, Kluth, M, Minner, S, Tsourlakis, MC, Izbicki, JR, Sauter, G, Schlomm, T & Wilczak, W 2013, 'SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence', PROSTATE, vol. 73, no. 15, pp. 1690-8. https://doi.org/10.1002/pros.22707

APA

Grupp, K., Diebel, F., Sirma, H., Simon, R., Breitmeyer, K., Steurer, S., Hube-Magg, C., Prien, K., Pham, T., Weigand, P., Michl, U., Heinzer, H., Kluth, M., Minner, S., Tsourlakis, M. C., Izbicki, J. R., Sauter, G., Schlomm, T., & Wilczak, W. (2013). SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. PROSTATE, 73(15), 1690-8. https://doi.org/10.1002/pros.22707

Vancouver

Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S et al. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. PROSTATE. 2013 Nov 1;73(15):1690-8. https://doi.org/10.1002/pros.22707

Bibtex

@article{66ba5a116d314f9ebb0568fd98ce048c,
title = "SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence",
abstract = "BACKGROUND: The serine peptidase inhibitor, Kazal type 1 (SPINK1) has been suggested to define an aggressive molecular subtype of ERG-fusion negative prostate cancer. It was the aim of this study to further study the clinical relevance of SPINK1 expression and its relationship with other key genomic alterations of prostate cancer.METHODS: A tissue microarray containing more than 10,000 prostate cancers with clinical follow-up was used for immunohistochemical SPINK1 analysis. Data on ERG status as well as PTEN, 6q, 5q, and 3p deletions were available for comparison.RESULTS: SPINK1 expression was absent in benign prostate glands and detectable in 5.9% of 9,503 interpretable prostate cancers. Presence of SPINK1 expression was markedly more frequent in ERG negative (10.4%) than in ERG positive cancers (0.3%; P < 0.0001). However, SPINK1 expression was unrelated to tumor phenotype and biochemical recurrence in all cancers and in the subgroup of ERG negative cancers. Further subgroup analyses revealed, however, that--within ERG negative cancers--SPINK1 expression was significantly linked to deletions at 6q15 (P < 0.0001) and 5q21 (P = 0.0042).CONCLUSIONS: Our results exclude SPINK1 as a relevant prognostic prostate cancer biomarker. However, the data demonstrate that SPINK1 overexpression is tightly linked to the small subsets of 6q15- and 5q21-deleted ERG negative prostate cancers. These findings support the concept of molecularly defined subtypes of prostate cancers.",
keywords = "Adult, Aged, Aged, 80 and over, Carrier Proteins, Chromosomes, Human, Pair 5, Chromosomes, Human, Pair 6, Gene Deletion, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Tissue Array Analysis, Trans-Activators, Tumor Markers, Biological",
author = "Katharina Grupp and Franz Diebel and H{\"u}seyin Sirma and Ronald Simon and Karin Breitmeyer and Stefan Steurer and Claudia Hube-Magg and Kristina Prien and Taher Pham and Philipp Weigand and Uwe Michl and Hans Heinzer and Martina Kluth and Sarah Minner and Tsourlakis, {Maria Christina} and Izbicki, {Jakob R} and Guido Sauter and Thorsten Schlomm and Waldemar Wilczak",
note = "{\textcopyright} 2013 Wiley Periodicals, Inc.",
year = "2013",
month = nov,
day = "1",
doi = "10.1002/pros.22707",
language = "English",
volume = "73",
pages = "1690--8",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "15",

}

RIS

TY - JOUR

T1 - SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence

AU - Grupp, Katharina

AU - Diebel, Franz

AU - Sirma, Hüseyin

AU - Simon, Ronald

AU - Breitmeyer, Karin

AU - Steurer, Stefan

AU - Hube-Magg, Claudia

AU - Prien, Kristina

AU - Pham, Taher

AU - Weigand, Philipp

AU - Michl, Uwe

AU - Heinzer, Hans

AU - Kluth, Martina

AU - Minner, Sarah

AU - Tsourlakis, Maria Christina

AU - Izbicki, Jakob R

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Wilczak, Waldemar

N1 - © 2013 Wiley Periodicals, Inc.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: The serine peptidase inhibitor, Kazal type 1 (SPINK1) has been suggested to define an aggressive molecular subtype of ERG-fusion negative prostate cancer. It was the aim of this study to further study the clinical relevance of SPINK1 expression and its relationship with other key genomic alterations of prostate cancer.METHODS: A tissue microarray containing more than 10,000 prostate cancers with clinical follow-up was used for immunohistochemical SPINK1 analysis. Data on ERG status as well as PTEN, 6q, 5q, and 3p deletions were available for comparison.RESULTS: SPINK1 expression was absent in benign prostate glands and detectable in 5.9% of 9,503 interpretable prostate cancers. Presence of SPINK1 expression was markedly more frequent in ERG negative (10.4%) than in ERG positive cancers (0.3%; P < 0.0001). However, SPINK1 expression was unrelated to tumor phenotype and biochemical recurrence in all cancers and in the subgroup of ERG negative cancers. Further subgroup analyses revealed, however, that--within ERG negative cancers--SPINK1 expression was significantly linked to deletions at 6q15 (P < 0.0001) and 5q21 (P = 0.0042).CONCLUSIONS: Our results exclude SPINK1 as a relevant prognostic prostate cancer biomarker. However, the data demonstrate that SPINK1 overexpression is tightly linked to the small subsets of 6q15- and 5q21-deleted ERG negative prostate cancers. These findings support the concept of molecularly defined subtypes of prostate cancers.

AB - BACKGROUND: The serine peptidase inhibitor, Kazal type 1 (SPINK1) has been suggested to define an aggressive molecular subtype of ERG-fusion negative prostate cancer. It was the aim of this study to further study the clinical relevance of SPINK1 expression and its relationship with other key genomic alterations of prostate cancer.METHODS: A tissue microarray containing more than 10,000 prostate cancers with clinical follow-up was used for immunohistochemical SPINK1 analysis. Data on ERG status as well as PTEN, 6q, 5q, and 3p deletions were available for comparison.RESULTS: SPINK1 expression was absent in benign prostate glands and detectable in 5.9% of 9,503 interpretable prostate cancers. Presence of SPINK1 expression was markedly more frequent in ERG negative (10.4%) than in ERG positive cancers (0.3%; P < 0.0001). However, SPINK1 expression was unrelated to tumor phenotype and biochemical recurrence in all cancers and in the subgroup of ERG negative cancers. Further subgroup analyses revealed, however, that--within ERG negative cancers--SPINK1 expression was significantly linked to deletions at 6q15 (P < 0.0001) and 5q21 (P = 0.0042).CONCLUSIONS: Our results exclude SPINK1 as a relevant prognostic prostate cancer biomarker. However, the data demonstrate that SPINK1 overexpression is tightly linked to the small subsets of 6q15- and 5q21-deleted ERG negative prostate cancers. These findings support the concept of molecularly defined subtypes of prostate cancers.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carrier Proteins

KW - Chromosomes, Human, Pair 5

KW - Chromosomes, Human, Pair 6

KW - Gene Deletion

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Prostate

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Tissue Array Analysis

KW - Trans-Activators

KW - Tumor Markers, Biological

U2 - 10.1002/pros.22707

DO - 10.1002/pros.22707

M3 - SCORING: Journal article

C2 - 23843146

VL - 73

SP - 1690

EP - 1698

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 15

ER -